Series B · Biotech · Berlin, Germany · Founded 2019 · 51–201 employees
Avextra is one of Europe's leading vertically-integrated medical cannabis operators developing regulator-approved cannabis-based medicines. Founded in 2019, the company controls the entire value chain from cultivation in Portugal to EU-GMP certified extraction and manufacturing in Germany. They've raised €21.54M in Series B funding in 2024 and are conducting multiple Phase II clinical trials including OCEAN for chemotherapy-induced neuropathic pain and NEUROBIS for neurodegenerative diseases. The company has successfully expanded across Europe with exports to UK, Italy, Switzerland and Austria.